Roche

FDA to decide on TG Therapeutics’ lymphoma drug early next year
FDA to decide on TG Therapeutics’ lymphoma drug early next year
Pharmaforum
TG Therapeutics
FDA
lymphoma
umbralisib
Bristol-Myers Squibb
Roche
Flag link:
Roche pulls a tumor micro-environment drug out of the freezer, hands it to a UK upstart
Roche pulls a tumor micro-environment drug out of the freezer, hands it to a UK upstart
Endpoints
Roche
Celleron Therapeutics
solid tumors
Flag link:
Eisai is creating a new US corporate, R&D HQ in Roche’s old Nutley, NJ campus
Eisai is creating a new US corporate, R&D HQ in Roche’s old Nutley, NJ campus
Endpoints
Eisai
Roche
R&D
New Jersey
Flag link:
Hits, but mostly misses for Roche’s 4 late-stage trials of GI drug hopeful etrolizumab
Hits, but mostly misses for Roche’s 4 late-stage trials of GI drug hopeful etrolizumab
Fierce Biotech
Roche
Genentech
etrolizumab
clinical trials
ulcerative colitis
Flag link:
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
Xconomy
Roche
risdiplam
SMA
spinal muscular atrophy
FDA
Flag link:
In surprising setback, combo of Roche’s Tecentriq and chemo fails to help patients with triple-negative breast cancer
In surprising setback, combo of Roche’s Tecentriq and chemo fails to help patients with triple-negative breast cancer
Endpoints
Roche
FDA
triple negative breast cancer
Tecentriq
Flag link:
Dicerna guides Roche-partnered hepatitis B drug past early test
Dicerna guides Roche-partnered hepatitis B drug past early test
Fierce Biotech
Roche
Dicerna Pharmaceuticals
hepatitis B
RG6346
clinical trials
Flag link:
FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
Pharmaceutical Business Review
Roche
FDA
Tecentriq
Cotellic
Zelboraf
melanoma
Flag link:
Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge
Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge
Pharmaforum
Roche
Tecentriq
FDA
melanoma
Bristol-Myers Squibb
Merck
Flag link:
Roche’s tocilizumab fails to achieve primary endpoints for Covid-19-related pneumonia
Roche’s tocilizumab fails to achieve primary endpoints for Covid-19-related pneumonia
Pharmaceutical Business Review
Roche
Actemra
RoActemra
COVID-19
clinical trials
COVID-19 pneumonia
Flag link:
Roche doubles down on Tau
Roche doubles down on Tau
EP Vantage
Roche
anti-tau antibodies
UCB Pharma
UCB01017
Alzheimer's disease
Flag link:
Go or no go? Valuable drugs set for FDA decisions
Go or no go? Valuable drugs set for FDA decisions
EP Vantage
FDA
drug approvals
Novartis
inclisiran
Biomarin
valrox
Roche
risdiplam
GSK
belantamab mafodotin
Gilead Sciences
Galapagos
filgotinib
Flag link:
Roche drops hep B antiviral as late-stage pipeline tests 'largely on track' despite COVID-19 disruption
Roche drops hep B antiviral as late-stage pipeline tests 'largely on track' despite COVID-19 disruption
Fierce Biotech
Roche
antiviral
hepatitis B
RG6217
Flag link:
Roche, Jnana sign multi-target collaboration deal for small molecule drugs
Roche, Jnana sign multi-target collaboration deal for small molecule drugs
Pharmaceutical Business Review
Roche
Jnana Therapeutics
small molecule drugs
Flag link:
Roche suffers double whammy as biosimilars, COVID-19 joined hands in weak quarter
Roche suffers double whammy as biosimilars, COVID-19 joined hands in weak quarter
Fierce Pharma
Roche
earnings
Flag link:
10 drugmakers expected to make the most money in the next 5 years
10 drugmakers expected to make the most money in the next 5 years
Beckers Hospital Review
Roche
pharma industry
drug sales
Flag link:
10 most valuable R&D projects in the pharmaceutical industry pipeline
10 most valuable R&D projects in the pharmaceutical industry pipeline
Beckers Hospital Review
R&D
drug development
Eli Lilly
Novartis
Argenx
Bristol-Myers Squibb
Vir Biotechnolgy
Biogen
GSK
Iovance
Roche
Flag link:
Roche, PicnicHealth start RWD partnership with multiple sclerosis focus
Roche, PicnicHealth start RWD partnership with multiple sclerosis focus
MedCity News
Roche
PicnicHealth
MS
multiple sclerosis
RWD
real world data
artificial intelligence
Flag link:
Alzheimer’s catalysts round off a year dominated by Biogen
Alzheimer’s catalysts round off a year dominated by Biogen
EP Vantage
Alzheimer's disease
Roche
Eli Lilly
AC Immune
Biohaven
Cortexyme
Biogen
Flag link:
Roche, Blueprint Medicines sign $1.7bn worth deal for pralsetinib
Roche, Blueprint Medicines sign $1.7bn worth deal for pralsetinib
Pharmaceutical Business Review
Roche
Blueprint Medicines
pralsetinib
RET-altered cancer
Flag link:

Pages